Healthcare Industry Leaders Unite Around Patient Safety at Glytec’s Inaugural Conference on Glycemic Innovation and Collaboration Conference Identifies Key Strategies and Actionable Insights for Hospitals to Optimize Glycemic Management Ahead of New CMS Core Measures WALTHAM, MASS. (August 31, 2021) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today revealed details about its …
Glytec Research Presented at American Diabetes Association’s 81st Scientific Sessions Shows Low Hypoglycemia for Adults with T1D Treated with eGlycemic Management System Largest study to analyze T1D Patients With and Without DKA finds Glucommander insulin management software can safely keep blood glucose levels in range WALTHAM, MASS. (June 22, 2021) – Glytec, the only provider of cloud-based insulin management software …
Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals Collaboration Seeks to Improve Outcomes and Reduce Cost of Care for the 25% of Veterans with Diabetes WALTHAM, MASS. (July 7, 2020) – Glytec, the only provider of insulin management software across the continuum of care, and ThunderCat Technology, a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology …
Glytec’s Glucommander Software Combined with Continuous Glucose Monitoring Enables Patients with Diabetes to Improve Time in Range by More than 25% in Only Four Weeks First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources WALTHAM, MASS. (June 16, 2020) – Glytec, the only provider of insulin management software across …
Healthcare Providers Showcase Value of Glytec’s Insulin Management Software During Diabetes Technology Society’s Virtual Hospital Poster Session Event Includes Six Studies on Quality and Cost Improvements Achieved Through Glytec eGMS® WALTHAM, MASS. (June 11, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that healthcare providers from five separate health systems will present studies …
Healthcare Providers Share Results of Computer-Guided Insulin Dosing through Glytec During Diabetes Technology Society’s Virtual Hospital Meeting AdventHealth and CHI Franciscan Lead Three-Part Session with Data on Quality and Cost Improvements Achieved Through Electronic Glucose Management WALTHAM, Mass. (April 22, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that AdventHealth and …
COVID-19 Study Shows More than 4 Times In-Hospital Mortality Rate and Increased Length of Stay for Patients with Diabetes and Hyperglycemia Glytec Research Reveals New Insights Into Important Risk Factors for the Large Population of COVID-19 Patients with Glycemic Control Issues WALTHAM, MASS. (April 17, 2020) – Glytec, the only provider of insulin management software across the continuum of care, …
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
Our client, Hawaii Pacific Health, was named a HIMSS Enterprise Davies Award recipient based in part on its success implementing Glytec’s eGlycemic Management System® to support computer-based insulin dosing and a new hypoglycemia protocol.
The results were better glucose control with computer-directed insulin dosing system versus usual care. 39.8% of all glucose values in the ICU setting were above the recommended limit (glucose 180 mg/dl) with usual care. With computer-directed insulin dosing system for intravenous insulin, the hyperglycemia rate was much lower representing just 16.6% of all glucose values.
Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.
The march toward value-based care is occurring on many fronts, with diabetes quality metrics front and center. Providers from giant hospital systems to primary care practices are looking for ways to find savings—and make patients healthier. In this mix is Glytec, a 10-year-old company founded on the idea that taking guesswork and time out of insulin dosing, first in hospital settings and then outside them, could dramatically reduce episodes of hypo- and hyperglycemia. This would provide savings and lead to better glycated hemoglobin (A1C) levels for patients with previously uncontrolled diabetes.
Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.
Using glycemic management software that integrates with its EHR system, a Virginia hospital system has achieved a 79% improvement over the national average for hyperglycemia rates.
Doctors and nurses following the standard of care in hospitals aren’t just paying more attention to analytics. These days, the algorithm can be the cornerstone of superior care. Consider the tricky process of controlling the glycemic levels of patients with diabetes. At eight-hospital, Virginia-based Sentara Healthcare, this translates into a 79% improvement over the national average for hyperglycemia rates. These hospitals have achieved an overall hypoglycemia rate of 0.83 percent, which hospital officials says is a remarkable blended rate for IV and subcutaneous insulin therapy.
Hospitals have often had trouble managing patients with hyperglycemia and hypoglycemia. To help remedy that problem, Sentara Healthcare has ushered in a new standard of care in glucose management.
In 2008, Sentara saw several of its patients die due to poor management of their diabetes. There were several devastating events of prolonged hypoglycemia that resulted in permanent brain damage for patients, says Paul Chidester, M.D., vice president of medical affairs at the Va.-based Sentara Norfolk General Hospital within the health system. Sentara had reached a point when it knew it needed to do something to improve the care of its diabetes patients. “We sort of tolerated poor control of hyperglycemia and viewed episodes of hypoglycemia as a rite of passage of being in the hospital,” Chidester admits. [We said] poor control happens, just live with it. We then realized the negative impact that had on our patients, and decided that it had to change.”
Poster presented during AACE shows improved outcomes using Glytec’s subcutaneous insulin dosing solution versus traditional basal bolus insulin therapy.
Glytec, a clinical information technology company solely dedicated to the mission of improving insulin management and glycemic control, is pleased to share the results of a late-breaking poster that was presented at the American Association of Clinical Endocrinologists (AACE) 23rd Annual Scientific and Clinical Congress. The poster is based on results experienced by Sentara Healthcare during the first 30 days after using Glytec’s Glucommander™ SubQ to manage subcutaneous Basal Bolus Insulin (BBI) therapy. The poster was presented by Joseph Aloi, MD, clinical director of the Strelitz Diabetes Center at Eastern Virginia Medical School, during the Congress’s general poster session.
Leading hospital system achieves dramatic reductions in occurrences of hyperglycemia and hypoglycemia, reduces length of stay.
Sentara Healthcare, a 12-hospital, not-for-profit health system serving Virginia and northeastern North Carolina, widely recognized for clinical excellence and IT innovation, today announced that they have achieved dramatic improvements in inpatient glucose management through the utilization of the eGlycemic Management System® (eGMS®), developed by Glytec.